文献速递MDS 与骨髓增殖性肿瘤

预测真性红细胞增多症后及原发性血小板增多症后骨髓纤维化患者生存的临床-分子预后模型

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
PubMed 文献 · Leukemia · 2017-05-31

研究纳入685例JAK2、CALR和MPL注释的继发性骨髓纤维化(SMF)患者,通过惩罚Cox回归建立MYSEC-PM预后模型。模型将血红蛋白<11 g/dl、外周血原始细胞≥3%和CALR未突变各赋2分,血小板<150×10^9/l和体质性症状各赋1分,年龄每岁赋0.15分,将患者分为低危、中危-1、中危-2和高危四组,中位生存分别为未达到、9.3年、4.4年和2年(P<0.0001)。

要点

  • MYSEC-PM模型纳入血红蛋白<11 g/dl、外周血原始细胞≥3%、CALR未突变、血小板<150×10^9/l、体质性症状和年龄。
  • 模型将SMF患者分为低危、中危-1、中危-2和高危四组,中位生存分别为未达到、9.3年、4.4年和2年(P<0.0001)。
  • MYSEC-PM被认为是SMF临床决策和试验设计中最合适的工具。

核心结论

  • MYSEC-PM模型可预测继发性骨髓纤维化(SMF)患者生存,并被认为是SMF临床决策和试验设计中最合适的工具。

研究设计与样本

  • 研究纳入685例经JAK2、CALR和MPL注释的继发性骨髓纤维化(SMF)患者,通过惩罚Cox回归识别生存负性预测因子并构建预后模型。

主要发现

  • 整个队列的中位生存为9.3年(95% CI:8-未达到)。
  • 根据β风险系数赋分:血红蛋白<11 g/dl、外周血原始细胞≥3%和CALR未突变各2分;血小板<150×10^9/l和体质性症状各1分;年龄每岁0.15分。
  • MYSEC-PM将SMF患者分为四组,中位生存分别为:低危未达到(133例)、中危-1 9.3年(95% CI:8.1-未达到;245例)、中危-2 4.4年(95% CI:3.2-7.9;126例)、高危2年(95% CI:1.7-3.9;75例),组间差异P<0.0001。

临床怎么用

  • 作者认为MYSEC-PM是SMF临床决策和试验设计中最合适的工具。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as secondary myelofibrosis (SMF). No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF. Median survival of the whole cohort was 9.3 years (95% CI: 8-not reached-NR-). Through penalized Cox regressions we identified negative predictors of survival and according to beta risk coefficients we assigned 2 points to hemoglobin level <11 g/dl, to circulating blasts ⩾3%, and to CALR-unmutated genotype, 1 point to platelet count <150 × 109/l and to constitutional symptoms, and 0.15 points to any year of age. Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) allocated SMF patients into four risk categories with different survival (P<0.0001): low (median survival NR; 133 patients), intermediate-1 (9.3 years, 95% CI: 8.1-NR; 245 patients), intermediate-2 (4.4 years, 95% CI: 3.2-7.9; 126 patients), and high risk (2 years, 95% CI: 1.7-3.9; 75 patients). Finally, we found that the MYSEC-PM represents the most appropriate tool for SMF decision-making to be used in clinical and trial settings.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017. PMID: 28561069. doi:10.1038/leu.2017.169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。